1
|
Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Ruiz A, García-Sáenz JA, Torres R, de la Haba J, García E, Gómez HL, Llombart A, Rodríguez de la Borbolla M, Baena JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Castellanos J, Rodríguez-Lescure A, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Lluch A. Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs2-04] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adjuvant capecitabine (X) after completion of standard treatment in early TNBC pts.
Materials and Methods: Patients with operable, node-positive (or node-negative with tumor size ≥ 1 cm), centrally confirmed hormone receptor-negative, HER2-negative early BC, who had received 6–8 cycles (cy) of standard anthracycline and/or taxane-containing chemotherapy or 4 cy of doxorubicin-cyclophosphamide (for node-negative disease) in the (neo)adjuvant setting, were eligible. Patients were randomized to either 8 cy of X (1,000 mg/m2 bid, days 1–14, every 3 weeks) or observation. Stratification factors included center, prior taxane-based therapy, number of involved axillary lymph nodes and phenotype (basal vs non-basal, according to cytokeratins 5/6 and/or EGFR positivity). The primary objective was to compare the disease-free survival (DFS) between both treatment arms, and secondary objectives included the comparison in terms of 5-year DFS, overall survival (OS) and safety. Assuming a 30% risk reduction in DFS rate at 5 years (from 64.7% to 73.7%, hazard ratio 0.70) with 80% power and a two-tailed log-rank test at 0.05, 834 evaluable pts were needed. 876 pts had to be finally enrolled considering a drop-out rate of 5%.
Results: Recruitment of 876 pts from 8 countries was completed in September 2011. Median age was 49 years; 68.5% of pts were postmenopausal, 55.5% were lymph node negative, 71.7% had a basal phenotype, 67.5% received chemotherapy based on anthracyclines and taxanes. Median follow-up was 7.3 years (range 0.0 to 11.1). DFS was not significantly prolonged with X vs observation (hazard ratio (HR) 0.82; 95% confidence interval (CI), 0.63 to 1.06; P=0.1353). Five-year DFS was 79.6% (95% CI, 75.8% to 83.4%) with X and 76.8% (95% CI, 72.7% to 80.9%) with observation. OS was not statistically different between treatment arms (HR 0.92; 95% CI, 0.66 to 1.28; P=0.6228). In subgroup analysis for DFS, we found no statistically significant interaction between X treatment and different subgroups, with the exception of basal vs non-basal phenotypes (basal HR 0.97, 95% CI 0.72 to 1.32, P=0.8620; non-basal HR 0.51, 95% CI, 0.31 to 0.86, P=0.0101; interaction P=0.0357). Similar results were found for OS (basal HR 1.20, 95% CI 0.81 to 1.77, P=0.3684; non-basal HR 0.48, 95% CI, 0.26 to 0.91, P=0.0205; interaction P=0.0155). 75.2% of pts completed 8 cy of X, with a median relative dose intensity of 86.3%. Grade (G) 3 or higher adverse events (AEs) were observed in 40.4% of pts in X arm. In 9.6% of pts the AEs were related with X. Hand-foot syndrome was the most common AE in X arm (G3 on 18.8% of pts).
Conclusions: In our study, the addition of adjuvant X after standard (neo) adjuvant anthracycline and/or taxane-containing chemotherapy was not associated with a statistically significant improvement of DFS or OS compared to observation in pts with early TNBC. However, in a subgroup analysis a significant DFS and OS improvement was observed with X in pts with non-basal phenotype.
Sponsor: CIBOMA.
Citation Format: Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Ruiz A, García-Sáenz JA, Torres R, de la Haba J, García E, Gómez HL, Llombart A, Rodríguez de la Borbolla M, Baena JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Castellanos J, Rodríguez-Lescure A, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Lluch A. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS2-04.
Collapse
Affiliation(s)
- M Martín
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - CH Barrios
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - L Torrecillas
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - M Ruiz-Borrego
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Bines
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Segalla
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Ruiz
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - JA García-Sáenz
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - R Torres
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J de la Haba
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - E García
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - HL Gómez
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Llombart
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - M Rodríguez de la Borbolla
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - JM Baena
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Barnadas
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - L Calvo
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - L Pérez-Michel
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - M Ramos
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Castellanos
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Rodríguez-Lescure
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Cárdenas
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Vinholes
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - E Martínez de Dueñas
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - MJ Godes
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - MA Seguí
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Antón
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - P López-Álvarez
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - J Moncayo
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - G Amorim
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - E Villar
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - S Reyes
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - C Sampaio
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - B Cardemil
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - MJ Escudero
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - S Bezares
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - E Carrasco
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| | - A Lluch
- Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; In
| |
Collapse
|
2
|
Martín M, de la Torre-Montero JC, López-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, González Del Val R, Del Monte-Millan M, Massarrah T, Vila C, García-Paredes B, García-Sáenz JA, Lluch A. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat 2018; 171:627-634. [PMID: 29923063 PMCID: PMC6133184 DOI: 10.1007/s10549-018-4855-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 06/13/2018] [Indexed: 11/29/2022]
Abstract
Background Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. Patients and methods BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1.5 to 5 years following primary diagnosis searching for PA. A confirmatory prevalence study was later performed in other two institutions. Finally, a prevention study using prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps in patients receiving adjuvant docetaxel was performed. Results In the initial prevalence study (492 patients), minor forms of PA (grade 1) were recorded with all chemotherapy regimens and aromatase inhibitors. Patients receiving docetaxel regimens at cumulative dose (CD) ≥ 400 mmg/m2 presented a significantly higher prevalence of grades 1 PA (33–52%) and 2 PA (5–12%). Prevalence of grade 2 PA with docetaxel CD ≥ 400 mmg/m2 was confirmed in two other institutions. Overall, grade 2 PA was seen in 10.06% (95% CI 7.36–13.61) of 358 patients with docetaxel regimens reaching CD ≥ 400 mmg/m2, but not in patients with lower docetaxel CD, other chemotherapy regimens, or endocrine therapy alone. In prevention trial, no grade 2 PA occurred among 116 patients receiving adjuvant docetaxel (≥ 400 mmg/m2) and PSC followed-up after a 96 months median time. PSC was well tolerated. No scalp relapses were seen among 30 patients (22% of all inclusions) having disease relapse. Conclusion Adjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762. Electronic supplementary material The online version of this article (10.1007/s10549-018-4855-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- M Martín
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain. .,Hospital General Universitario Gregorio Marañón, Medical Oncology Service, Calle Maiquez, no. 9, 28007, Madrid, Spain.
| | - J C de la Torre-Montero
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.,Universidad Pontificia Comillas, Madrid, Spain
| | - S López-Tarruella
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - K Pinilla
- Medical Oncology Department, Hospital Clínico Universitario, CIBERONC, Valencia, Spain
| | - A Casado
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - S Fernandez
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.,Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - Y Jerez
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - J Puente
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - I Palomero
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - R González Del Val
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - M Del Monte-Millan
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - T Massarrah
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain
| | - C Vila
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - B García-Paredes
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - J A García-Sáenz
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - A Lluch
- Medical Oncology Department, Hospital Clínico Universitario, CIBERONC, Valencia, Spain
| |
Collapse
|
3
|
Martín M, Hoffman J, Ruiz-Borrego M, Muñoz M, Calvo L, Crownover P, García-Sáenz JA, Alba E, Wang D, Thallinger C, Stradella A, Montaño Á, Adamo B, Antolín S, Moreno-Antón F, Falo C, Ruiz V, Martín N, Caballero R, Carrasco E, Gil-Gil M. Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Palbociclib (PAL) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that is under investigation in multiple oncologic clinical trials and is currently approved for use in combination with aromatase inhibitors (AIs) or fulvestrant (FUL) in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (BC).
The PEARL Study is an ongoing international, open label, controlled, randomized Phase 3 study comparing the efficacy and safety of PAL in combination with endocrine therapy (exemestane [EXE] or FUL) versus capecitabine in postmenopausal women with HR+/ HER2– metastatic BC whose disease progressed on AIs. A secondary objective of the study was to evaluate the pharmacokinetics (PK) of PAL (125mg QD, 3 weeks on/1 week off) and EXE (25mg QD, continuously) when coadministered. This is the first study to investigate the drug-drug interaction (DDI) potential of the combination of PAL and the AI EXE.
Methods: Patients (pts) randomized to the PAL+EXE arm of the PEARL Study in seven selected sites had the option of participating in the PK sub-study. Those who enrolled in the PK sub-study received EXE alone in a 7-day lead-in period immediately prior to Cycle 1 Day 1, when both drugs were coadministered on their standard dosing regimens. Sub-study pts were to have 2 pre-dose plasma PK samples drawn at steady-state (ss) during the lead-in period ("EXE Alone") for EXE determination, and 2 ss PK samples drawn for EXE and PAL determination (2 per analyte) during coadministration ("PAL+EXE"). Plasma concentrations of PAL and EXE were measured using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. The withinpatient mean concentration of the PK samples which met ss acceptance criteria (WPM-Ctrough) for each analyte were generated for each treatment period as the input for DDI analyses.
To assess the effect of coadministration of PAL on EXE PK, the WPM-Ctrough of EXE was compared within patients between the "PAL+EXE" (Test) and "EXE Alone" (Reference) treatment periods using a one-way analysis of variance (ANOVA) model with treatment as a fixed effect and patient as a random effect. To assess the effect of coadministration of EXE on PAL PK, the WPM-Ctrough of PAL was compared between the "PAL+EXE" period (Test) and historical data (Reference) using an ANOVA model. Analysis of covariance (ANCOVA) models were used to assess the impact of demographic differences between analysis populations in covariates known to impact PAL PK on the ANOVA model conclusions.
Results: A total of 26 pts randomized to the PAL+EXE arm were enrolled in the PK sub-study and had PK samples analysed, of which 23 meet ss acceptance criteria. The ratio of the adjusted geometric means for EXE WPM-Ctrough was 106.9% (90%CI: 82.4-138.8), when EXE was administered with PAL, compared with its administration alone. Likewise, the models to assess potential for EXE to perpetrate DDI on PAL PK showed ratios of adjusted geometric means of 102.4% (90%CI: 82.0-127.9) and 111.6% (90%CI: 90.3137.8), when adjusted for covariates.
Conclusion: The PK data indicate a lack of a clinically meaningful DDI between PAL and EXE when the 2 drugs are coadministered.
Sponsor: GEICAM
Citation Format: Martín M, Hoffman J, Ruiz-Borrego M, Muñoz M, Calvo L, Crownover P, García-Sáenz JA, Alba E, Wang D, Thallinger C, Stradella A, Montaño Á, Adamo B, Antolín S, Moreno-Antón F, Falo C, Ruiz V, Martín N, Caballero R, Carrasco E, Gil-Gil M. Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-23.
Collapse
Affiliation(s)
- M Martín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - J Hoffman
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Ruiz-Borrego
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Muñoz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - L Calvo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - P Crownover
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - JA García-Sáenz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - E Alba
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - D Wang
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - C Thallinger
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - A Stradella
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - Á Montaño
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - B Adamo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - S Antolín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - F Moreno-Antón
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - C Falo
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - V Ruiz
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - N Martín
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - R Caballero
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - E Carrasco
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| | - M Gil-Gil
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Pfizer, Inc, CA; Hospital Universitario Virgen del Rocío, Madrid, Spain; Hospital Universitari Clinic de Barcelona, Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, A Coruna, Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga, Spain; Univ. Klinik für Innere Medizin I, Währinger Gürtel, Vienna, Austria; Institut Catalá d'Oncologia (ICO), L'Hospitalet, Barcelona, Spain; Pfizer, Inc., CT
| |
Collapse
|
4
|
Jiménez-Ballvé A, García García-Esquinas M, Salsidua-Arroyo O, Serrano-Palacio A, García-Sáenz JA, Ortega Candil A, Fuentes Ferrer ME, Rodríguez Rey C, Román-Santamaría JM, Moreno F, Carreras-Delgado JL. Prognostic value of metabolic tumour volume and total lesion glycolysis in 18F-FDG PET/CT scans in locally advanced breast cancer staging. Rev Esp Med Nucl Imagen Mol 2018; 35:365-372. [PMID: 26948652 DOI: 10.1016/j.remn.2016.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Revised: 01/19/2016] [Accepted: 01/26/2016] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients. MATERIAL AND METHODS Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A 18F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB). RESULTS Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P=.020 and P=.028, respectively); whereas SUVmax in the lymph nodes (N) was significantly related (P=.008) to the recurrence rate. The best cut-off points to predict recurrence where: MTV T ≥19.3cm3, TLG T≥74.4g and SUVmax N≥13.8, being 10-12 times more likely to recidivate when these thresholds where exceeded. Tumour grade was the only clinical-pathological variable which was related to recurrence probability (p=.035). CONCLUSIONS In this study of LABC patients the metabolic parameters which have a better relationship with recurrence rate are: MTV and TLG in the primary tumour, SUVmax in the regional lymph node disease and whole-body PET data.
Collapse
Affiliation(s)
- A Jiménez-Ballvé
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España.
| | - M García García-Esquinas
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - O Salsidua-Arroyo
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - A Serrano-Palacio
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - J A García-Sáenz
- Servicio de Oncología Médica, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - A Ortega Candil
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - M E Fuentes Ferrer
- Unidad de Gestión Clínica de Medicina Preventiva, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - C Rodríguez Rey
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - J M Román-Santamaría
- Servicio de Ginecología y Obstetricia, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - F Moreno
- Servicio de Oncología Médica, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| | - J L Carreras-Delgado
- Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, España
| |
Collapse
|
5
|
García-Sáenz JA, Carrasco E, Kneissl ML, Zohren F, Martin M. Abstract OT2-01-21: Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Standard therapy for ER-positive tumors in the adjuvant and metastatic settings is antiestrogen therapy, including aromatase inhibitors (AI); however, resistance is common. These tumors may respond to alternative second-line anti-estrogen therapies such as fulvestrant but response durations are often short. Preclinical and clinical studies suggest that simultaneous inhibition of ER and PI3K/mTOR could prevent/delay the emergence of hormone-independent cancer cells thereby improving patient (pt) outcomes. This study will test whether fulvestrant plus TAK-228, a dual TORC1/2 inhibitor, can overcome endocrine therapy resistance in ER-positive breast cancer. This is an open-label, randomized, 3-arm, phase 2 study of continuous once-daily TAK-228 (oral, 4 mg) or once-weekly TAK-228 (oral, 30 mg) plus fulvestrant (500 mg intramuscularly on d1 and d15 of cycle 1 [loading regimen] then d1 of each subsequent 28-d cycle), compared with fulvestrant alone, in pts with advanced or metastatic ER-positive/HER2-negative breast cancer that has progressed during/after AI therapy. Pts will be randomized 1:1:1 to the 3 arms and stratified at randomization via presence or absence of visceral metastasis, prior hormonal therapy sensitivity, and prior exposure to CDK 4/6 inhibitors. Pts will receive study drug(s) until progressive disease (PD), unacceptable toxicity, or consent withdrawal. Postmenopausal women ≥18 yrs old with local histological confirmation of ER-positive/HER2-negative metastatic or advanced breast cancer; with measureable disease; ECOG status 0–1; PD during/after prior AI therapy (defined as progression ≤12 mos after discontinuing adjuvant therapy or ≤1 mo after discontinuation in the metastatic setting) and adequate organ function are eligible. Exclusion criteria include prior therapy with mTOR inhibitors, PI3K inhibitors, dual PI3K-mTOR inhibitors, AKT inhibitors, or fulvestrant; prior treatment with >1 line of chemotherapy for metastatic breast cancer; experienced recurrent or progressive disease on >2 endocrine therapies for metastatic breast cancer; or significant previous/existing cardiac conditions. This study aims to determine the efficacy (primary endpoint: PFS; secondary endpoints: OS, TTP, ORR), safety and tolerability of daily and weekly TAK-228 plus fulvestrant compared with fulvestrant alone. The distribution of PFS will be analyzed via the Kaplan-Meier method. The primary hypothesis (TAK-228 plus fulvestrant can improve median PFS to 8 mos [hazard ratio, HR 0.5] vs fulvestrant-alone median PFS of 4 mos) is to be tested at the 0.10 significance level (2-sided; dropout rate 10%). A total of 72 PFS events are needed for each pair-wise comparison; p-values from a stratified log-rank test and HRs will be presented. The safety profile and clinical laboratory parameters (and/or change from baseline) for all scheduled measurements over time will be summarized by descriptive statistics. Approximately 153 pts (51 pts per arm) will be enrolled from approximately 55 study centers in North America and Spain; to date, no pts have been enrolled. For more information, please contact Michelle Kneissl at michelle.kneissl@takeda.com.
Citation Format: García-Sáenz JA, Carrasco E, Kneissl ML, Zohren F, Martin M. Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-21.
Collapse
Affiliation(s)
- JA García-Sáenz
- Hospital Clínico Universitario San Carlos, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), San Sebastian de los Reyes, Madrid, Spain; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - E Carrasco
- Hospital Clínico Universitario San Carlos, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), San Sebastian de los Reyes, Madrid, Spain; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - ML Kneissl
- Hospital Clínico Universitario San Carlos, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), San Sebastian de los Reyes, Madrid, Spain; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - F Zohren
- Hospital Clínico Universitario San Carlos, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), San Sebastian de los Reyes, Madrid, Spain; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - M Martin
- Hospital Clínico Universitario San Carlos, Madrid, Spain; GEICAM (Spanish Breast Cancer Group), San Sebastian de los Reyes, Madrid, Spain; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| |
Collapse
|
6
|
Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Abstract P3-07-42: Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The role of bevacizumab in combination with chemotherapy in metastatic BC is controversial, and no biomarker exists as of today that predicts benefit to this agent. In the LEA clinical trial, a numerical, statistically non-significant benefit from the addition of bevacizumab to endocrine therapy (ET) was observed in the first-line metastatic setting (18.4 vs. 13.8 months of Progression-Free Survival (PFS), p=0.14). Here, we explored various gene expression-based predictors of outcome and benefit to bevacizumab.
Methods and materials: LEA trial randomized 380 patients with HR+/HER2- advanced disease to bevacizumab in combination with ET (ET+B) vs. ET alone. Primary endpoint was PFS. Expression of BC selected genes was evaluated in formalin-fixed paraffin-embedded (FFPE) primary tumors using the nCounter platform from patients randomized in Spain that consent for biomarker analyses. The following variables were evaluated: 1) research-based PAM50 intrinsic subtypes (categorical variable; Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like); 2) research-based PAM50 signatures (continuous variable; scores showing the distant of the gene expression values of an individual sample compared to the centroid gene values for each PAM50 intrinsic subtype); 3) risk of recurrence (ROR) groups (low, medium and high); 4) the 13-gene hypoxia/VEGF signature (continuous); and 5) Ki67 by immunohistochemistry (continuous). Uni- and multivariable Cox models for PFS were used to test the prognostic significance of each variable. To determine whether each variable is predictive of bevacizumab benefit, we tested the interaction term of each variable by treatment arm in a Cox model.
Results: Tumor samples from 103 patients were analyzed: 55 (53%) in ET+B arm and 49 (47%) in ET arm. Subtype distribution was as follows: 57 (55.3%) Luminal A, 32 (31.1%) Luminal B, 5 (4.9%) HER2-enriched, 1 (1.0%) Basal-like, and 8 (7.8%) normal-like. In a univariate analysis, Luminal B tumors had a poorer outcome using Luminal A as reference (13.8 vs. 21.3 months, respectively; (hazard ratio, HR=1.80, 95% CI 1.10-2.95, p=0.019). Concordant with this finding, Luminal A signature was associated with a better outcome. Similarly, ROR-P high group showed a poorer outcome than ROR-P low group (8.5 vs. 19.4 months; HR=2.88, 95% CI 1.30-6.35, p=0.009). Neither VEGF-13 signature nor Ki67 were found to be associated with PFS. Similar findings were obtained after adjustment for treatment, age, previous ET, ECOG, visceral disease and number of metastatic sites. In terms of treatment benefit, the HER2-enriched signature was the only variable found predictive of bevacizumab PFS benefit in univariate (p=0.010) and multivariate (p=0.015) analyses.
Conclusions: In advanced HR+/HER2- disease, intrinsic subtype (i.e. Luminal A vs. B) independently predicts PFS following first-line ET. In addition, HR+/HER2-negative tumors with high expression of the HER2-enriched signature, a biomarker of estrogen-independence, benefit the most from bevacizumab. Further validation of these prognostic and predictive biomarkers is warranted.
Citation Format: Prat A, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-42.
Collapse
Affiliation(s)
- A Prat
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J de la Haba-Rodriguez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - Á Guerrero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - JA García-Sáenz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Morales
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Antón
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Muñoz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Ramos
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - N Martínez-Jáñez
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Margelí
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S Servitja
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - F Rojo
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Galván
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - S González
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - J Cruz
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - P Sánchez-Rovira
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - A Perelló
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - C Rodríguez-Martin
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Casas
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - E Carrasco
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - R Caballero
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| | - M Martín
- Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)– H. Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Fundación Jiménez Díaz, Madrid, Spain; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario de Canarias, La Laguna, Tenerife, Spain; Complejo Hospitalario de Jaén, Jaén, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; GEICAM, Spanish Breast Cancer Group, Madr
| |
Collapse
|
7
|
García García-Esquinas M, García-Sáenz JA, Arrazola García J, Enrique Fuentes Ferrer M, Furió V, Rodriguez Rey C, Román JM, Carreras Delgado JL. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors. Q J Nucl Med Mol Imaging 2014; 58:66-73. [PMID: 24104854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM Classical prognostic and predictive factors serve to predict outcome and response to neoadjuvant treatment in stage II and III breast cancer. The purpose is to determine the relation between the SUVmax of the locoregional disease with these classical prognostic factors. METHODS A prospective study including 43 stage II and III breast cancer patients was performed. In all the patients, two 18F-FDG PET-CT studies were performed before and after neoadjuvant chemotherapy. After this treatment, surgery and adjuvant treatment were carried out. To combine the information of the locoregional disease, the SUVmax of the lesion (tumor or abnormal lymphnodes) with the highest uptake was used. SUVmax and prognostic factors were studied with the Kruskal-Wallis non-parametric test and with the Mann-Whitney U. RESULTS A statistically significant association between elevated SUVmax value and absence of estrogen receptors (ER) expression (16 vs.. 10; P<0.019) was found. Locorregional disease with positive HER2 phenotype had a statistically significant SUVmax value greater than Luminal A (estrogen and/or progesterone positive receptors with Ki67<15%) and B (estrogen and/or progesterone positive receptors with Ki67≥to 15%) (13.4 vs. 7.9 and 8.9; P<0.022 and P<0.024, respectively). Triple negative phenotype disease had higher SUVmax than Luminal A and B (15.4; P<0.030 and P<0.038). Positive correlation between the percentage of the Ki67 Proliferation Index and SUVmax (P<0.007) was demonstrated. High grade disease had a higher SUVmax than low grade (P<0.004). CONCLUSION Locorregional SUVmax is associated to prognostic and predictive factors and reaffirms the utility of PET-CT as a tool in the common clinical practice.
Collapse
|
8
|
Romero A, García-Sáenz JA, Fuentes-Ferrer M, López Garcia-Asenjo JA, Furió V, Román JM, Moreno A, de la Hoya M, Díaz-Rubio E, Martín M, Caldés T. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol 2012; 24:655-61. [PMID: 23104719 DOI: 10.1093/annonc/mds493] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Measurement of residual disease following neoadjuvant chemotherapy that accurately predicts long-term survival in locally advanced breast cancer (LABC) is an essential requirement for clinical trials development. Several methods to assess tumor response have been described. However, the agreement between methods and correlation with survival in independent cohorts has not been reported. PATIENTS AND METHODS We report survival and tumor response according to the measurement of residual breast cancer burden (RCB), the Miller and Payne classification and the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, in 151 LABC patients. Kappa Cohen's coefficient (К) was used to test the agreement between methods. We assessed the correlation between the treatment outcome and overall survival (OS) and relapse-free survival (RFS) by calculating Harrell's C-statistic (c). RESULTS The agreement between Miller and Payne classification and RCB classes was very high (К = 0.82). In contrast, we found a moderate-to-fair agreement between the Miller and Payne classification and RECIST criteria (К = 0.52) and RCB classes and RECIST criteria (К = 0.38). The adjusted C-statistic to predict OS for RCB index (0.77) and RCB classes (0.75) was superior to that of RECIST criteria (0.69) (P = 0.007 and P = 0.035, respectively). Also, RCB index (c = 0.71), RCB classes (c = 0.71) and Miller and Payne classification (c = 0.67) predicted better RFS than RECIST criteria (c = 0.61) (P = 0.005, P = 0.006 and P = 0.028, respectively). CONCLUSIONS The pathological assessment of tumor response might provide stronger prognostic information in LABC patients.
Collapse
Affiliation(s)
- A Romero
- Medical Oncology Department, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos, 28040 Madrid
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Romero A, Martín M, Oliva B, de la Torre J, Furio V, de la Hoya M, García-Sáenz JA, Moreno A, Román JM, Diaz-Rubio E, Caldés T. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol 2011; 23:1750-6. [PMID: 22052985 DOI: 10.1093/annonc/mdr483] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Identification of predicting factors for anthracyclines-based chemotherapy remains a clinical challenge. Glutathione S-transferase (GSTs) enzymes detoxify chemotherapy drugs and their metabolites. Several polymorphisms in GST genes result in reduced or no activity of the enzymes. Specifically, GSTM1 and GSTT1 genes are polymorphically deleted, the polymorphism GSTP1 c.313A>G (rs1695) determines the amino acid substitution Ile105Val, where the Val-containing enzyme has reduced activity. Also, GSTA1*B allele has reduced levels of GSTA1 enzyme. Several polymorphisms in GSTs have been associated with differences in survival for cancer patients treated with chemotherapy. PATIENTS AND METHODS We genotyped a total of five polymorphisms in GSTM1, GSTT1, GSTP1 and GSTA1 genes in 159 patients with locally advanced breast cancer, treated with single-agent doxorubicin or docetaxel (Taxotere). Gene expression microarrays were performed in 67 breast tumor samples. We correlate this data with treatment outcome. RESULTS In multivariate analysis, patients homozygous GG for GSTP1 c.313A>G SNP had a lower risk of chemoresistance when treated with doxorubicin (odds ratio 0.106; confidence interval 0.012-0.898; P=0.040). No association was found in the docetaxel arm. Also, we found that GSTP1 expression varied significantly among breast cancer molecular subtypes. CONCLUSIONS GSTP1 may constitute another tool contributing to individualized anthracycline-based therapy.
Collapse
Affiliation(s)
- A Romero
- Medical Oncology Department, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mesia R, Vázquez S, Grau JJ, García-Sáenz JA, Bayona C, Galceran JC, Irigoyen A, Lozano A, Mañós M, Cruz JJ. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6015 Background: TPF combination is the new standard IC. Adding cetuximab to PF chemotherapy is superior to PF alone in metastatic disease. We incorporated cetuximab into IC with TPF and subsequent radiotherapy (RT) in unresectable SCCHN. Methods: Phase II trial conducted in 7 Spanish hospitals. Previously untreated pts aged 18–70 yrs, ECOG PS 0–1 with unresectable SCCHN were eligible. Induction comprised T 75mg/m2 day 1, P 75mg/m2 day 1, F 750mg/m2 days 1–5, and cetuximab 250mg/m2 days 1, 8, and 15 (initial dose 400mg/m2 on cycle (C) 1, day 1), repeated every 21 days x 4 C, with prophylactic antibiotics and G-CSF support. Subsequently, pts received accelerated RT with a concomitant boost (69.9Gy) and cetuximab 250mg/m2 weekly. The primary endpoint was the objective response rate (RR) to cetuximab TPF as neoadjuvant therapy. Simon's optimal two-stage design was used to calculate the sample size of 49 evaluable pts. Results: 50 pts were enrolled: median age 54 yrs (33–68); 44 male; all stage IV (T4=31, N2–3=40). Primary sites were: oropharynx, 23; hypopharynx, 16; oral cavity, 5; larynx, 4.41(82%) pts received all 4 cycles of cetuximab TPF; 47 pts received ≥2 C and were evaluable for response using RECIST. 3 pts received <2 C (2 deaths from intercurrent disease and febrile neutropenia, 1 secondary neoplasm diagnosed). The table shows RR. Serious grade 3/4 adverse events (AEs) were: neutropenia 24%; neutropenic fever 20%; infection 6%; thrombocytopenia 4%; diarrhea 12%; hepatotoxicity 4%; hypomagnesemia 2%. Grade 3 AEs were: nausea/vomiting 2%; mucositis 6%; renal failure 4%; asthenia 4%; rash 4%; hypotension 4%. There were 2 AE-related deaths (febrile neutropenia and hepatic insufficiency). Conclusions: The addition of cetuximab to TPF IC in pts with unresectable SCCHN yields a high RR, mainly CR, potentially prolonging survival. Cetuximab TPF combination should be given to pts with good PS with specialized support provided. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- R. Mesia
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - S. Vázquez
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. J. Grau
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. A. García-Sáenz
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - C. Bayona
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. C. Galceran
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - A. Irigoyen
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - A. Lozano
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - M. Mañós
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. J. Cruz
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | | |
Collapse
|
11
|
García-Sáenz JA, Martín M, Maestro M, Vidaurreta M, Veganzones S, Rafael S, Casado A, Bobokova J, Sastre J, Arroyo M, Diaz-Rubio E. Circulating tumor cells in locally advanced breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22159 Background: A prospective study was conducted to determine the value of changes in circulating tumor cell (CTC) levels prior to and after the first cycle of neoadjuvant treatment in early prediction of pathologic response in locally advanced breast cancer (LABC). Methods: Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration. Results: Sixty patients (83.3%) had ≤1 CTC in the first sample and response rates in this cohort were: pathologic complete response (PCR) in 2 patients (5%); partial response (PR) in 35 (87.5%); stable disease (SD) in 2 (5%); progressive disease (PR) in 1 (2.5%). Twelve patients (16.7%) had ≥2 CTCs in the first sample; these patients were more likely to have triple negative tumors. All 12 had fewer CTCs in the second sample. Response rates in this second cohort of 12 patients were: PCR in 4 (34%); PR, 6 (50%); SD, 1 (8%); and PD, 1 (8%). pCR rate was markedly better in this second cohort (p<0.0042; OR 14.5, 95% CI 2.3–92). Conclusions: This study suggests that the presence of CTCs prior to neoadjuvant therapy might be a predictor of response to this therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - M. Martín
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - M. Maestro
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - M. Vidaurreta
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - S. Veganzones
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - S. Rafael
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - A. Casado
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - J. Bobokova
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - J. Sastre
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - M. Arroyo
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| | - E. Diaz-Rubio
- Clinico San Carlos Universitary Hospital, Madrid, Spain
| |
Collapse
|
12
|
García-Sáenz JA, Martín M, Calles A, Bueno C, Rodríguez L, Bobokova J, Custodio A, Casado A, Díaz-Rubio E. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 2009; 20:632-9. [PMID: 19028628 DOI: 10.1179/joc.2008.20.5.632] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A vascular endothelial growth factor (VEGF) inhibitor might enhance metronomic chemotherapy in previously treated metastatic breast cancer (MBC) patients. Anthracycline and taxane refractory MBC patients were given cyclophosphamide 50 mg p.o. daily, methotrexate 1 mg/kg i.v. every 14 days, and bevacizumab 10 mg/kg i.v. every 14 days. Trastuzumab was added in HER2-overexpressing tumors. 24 patients were enrolled and 22 were evaluable. All tumors had histologic grade II-III and most patients had > or =2 metastatic sites. After a median follow-up of 7.7 months the response rates were: complete response (CR) 0%, partial response (PR) 31.8% (95% CI 13.9- 54.9%), stable disease for >or =24 weeks (SD) 31.8% (95% CI 13.9-54.9%). Clinical benefit (CB= CR + PR + SD>24w) 63.6% (95% CI 40.7-82.8%). Median progression-free survival (PFS) was 7.5 months; overall survival (OS) was 13.6 months. HER2-overexpressing or high proliferative-index tumors had better 6-month PFS (75% vs. 34% in HER-negative tumors, P = 0.043; 67% vs. 0% in Ki-67 > or =20% tumors, P = 0.015). Adverse effects were mild. The combination of bevacizumab and a metronomic-based chemotherapy was effective, well tolerated and provided clinical benefit in heavilytreated MBC patients.
Collapse
Affiliation(s)
- J A García-Sáenz
- Service de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Bueno Muiño C, García-Sáenz JA, Santos Martín E, Sastre J, Mayol J, Díaz-Rubio E. Successful rectal cancer local recurrence radiofrequency ablation. Clin Transl Oncol 2008; 10:300-2. [PMID: 18490249 DOI: 10.1007/s12094-008-0202-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Local rectal cancer recurrences represent a great challenge, as surgical re-excisions or re-irradiation procedures are not always feasible. Moreover, scar or local recurrence is hard to elucidate with conventional diagnosis techniques. Emerging diagnostic and therapeutic procedures may be useful in this setting. A local rectal cancer recurrence radiofrequency ablation is reported. PET scan confirmed the recurrence, defined the target volume and assessed the success of the local therapy.
Collapse
Affiliation(s)
- C Bueno Muiño
- Servicio de Oncología Médica, Hospital Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
14
|
Bueno Muiño C, Puente Vázquez J, Sastre Valera J, García-Sáenz JA, Martín M, García Miralles N, Sánchez-Pernaute A, Díaz-Rubio E. Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Clin Transl Oncol 2007; 9:335-8. [PMID: 17525046 DOI: 10.1007/s12094-007-0063-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Locally advanced gastric adenocarcinoma has a poor outcome. Neoadjuvant treatment is being tested in locally advanced non-resectable tumours and in those resectable tumours with a high risk of recurrence. Efforts to identify prognostic factors and more active and less toxic preoperative regimens are being searched for. We report the case of a patient achieving a complete histopathological complete response following docetaxel- based neoadjuvant chemotherapy.
Collapse
Affiliation(s)
- C Bueno Muiño
- Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
García-Sáenz JA, Martín M, Casado A, Pérez-Segura P, Manrique I, Flores L, Macias JA, Cámara JC, Perezagua C, Díaz-Rubio E. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study. Rev Esp Quimioter 2002; 15:257-63. [PMID: 12582429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
A study was carried out to compare the use of prophylactic imipenem administered at the onset of profound neutropenia (immediate) with therapeutic imipenem administered at the onset of neutropenic fever (delayed) in cancer patients treated with high-dose chemotherapy. A total of 65 patients who were scheduled to receive two cycles of high-dose cyclophosphamide, etoposide, cisplatin (CEP) chemotherapy were randomized to receive imipenem either at presentation of neutropenia (immediate imipenem arm, prophylactic arm) or at commencement of neutropenic fever (delayed imipenem arm, therapeutic arm). Treatment was crossed over when the second CEP chemotherapy cycle was received. Of the 65 patients, 41 received the two planned cycles and 24 received only the first. Compared with the delayed imipenem arm, the immediate imipenem arm was associated with lower fever incidence (86.3% vs. 100%, p=0.0142) and Gram-negative bacteria infection [4/51 (7.8%) vs. 14/55 (25.5%), OR=0.24, p =0.031]. There were fewer episodes of pneumonia (2% vs. 12.7%), septic shock (0% vs. 3.6%) and deaths from infection (0% vs. 3.6%), but these differences did not reach statistical significance. With regard to delayed imipenem, for every seven patients with immediate imipenem, one episode of febrile neutropenia was avoided; for every six patients administered immediate imipenem, one case of Gram-negative infection was avoided; and for every nine patients administered immediate imipenem, one episode of pneumonia was avoided. There were no differences in the incidence of Gram-positive infections nor in the length of hospitalization between the two treatment arms. In conclusion, compared to its conventional delayed use, immediate imipenem significantly reduces the frequency of febrile neutropenia and Gram-negative infections in patients with high-dose chemotherapy.
Collapse
Affiliation(s)
- J A García-Sáenz
- Department of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bellido JL, García-Sáenz JA, Manzanares MA, Gutiérrez Zufiaurre MN, García-Rodríguez JA. [Resistance to macrolides in Streptococcus pyogenes]. Rev Esp Quimioter 1998; 11:196-204. [PMID: 9795305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- J L Bellido
- Departamento de Microbiología, Hospital Universitario de Salamanca, Paseo de San Vicente 108, 37007 Salamanca
| | | | | | | | | |
Collapse
|